42 results on '"Cano, Juana María"'
Search Results
2. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry
3. Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor
4. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
5. State of the scientific evidence and recommendations for the management of older patients with gastric cancer
6. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study
7. Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain
8. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
9. Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain
10. State of the scientific evidence and recommendations for the management of older patients with gastric cancer
11. Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis
12. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
13. sj-docx-5-tam-10.1177_17588359231157641 – Supplemental material for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
14. sj-docx-2-tam-10.1177_17588359231157641 – Supplemental material for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
15. sj-docx-1-tam-10.1177_17588359231157641 – Supplemental material for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
16. sj-docx-3-tam-10.1177_17588359231157641 – Supplemental material for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
17. sj-docx-4-tam-10.1177_17588359231157641 – Supplemental material for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
18. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer
19. 18F-FDG PET/contrast enhanced CT in the standard surveillance of high risk colorectal cancer patients
20. A Large Case-Control Study Performed in Spanish Population Suggests That RECQL5 Is the Only RECQ Helicase Involved in Breast Cancer Susceptibility
21. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study.
22. Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents
23. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
24. A large case-control study performed in Spanish population suggests that RECQL5 is the only RECQ helicase involved in breast cancer susceptibility
25. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
26. sj-docx-3-tam-10.1177_17588359211019672 – Supplemental material for External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
27. sj-docx-1-tam-10.1177_17588359211019672 – Supplemental material for External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
28. sj-docx-2-tam-10.1177_17588359211019672 – Supplemental material for External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
29. sj-docx-4-tam-10.1177_17588359211019672 – Supplemental material for External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
30. A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study
31. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
32. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
33. Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer
34. Differential clinicopathological and molecular features within late-onset colorectal cancer according to tumor location
35. Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry
36. Perfil Cognitivo y Psicolinguístico y su Relación con la Lectoescritura en un Preescolar con Síndrome de Down
37. Differential clinicopathological and molecular features within late-onset colorectal cancer according to tumor location
38. On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry
39. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer
40. A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li–Fraumeni-like families
41. 18 F-FDG PET/contrast enhanced CT in the standard surveillance of high risk colorectal cancer patients
42. ¹⁸F-FDG PET/contrast enhanced CT in the standard surveillance of high risk colorectal cancer patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.